Medication Adherence of Patient Assistance Program Recipients: A Pilot Study by Christian S. Conley, PharmD & Peter J. Hughes, PharmD, BCPS
Original Research  PHARMACY PRACTICE 
 
http://z.umn.edu/INNOVATIONS                      2012, Vol. 3, No. 3, Article 85                            INNOVATIONS in pharmacy    1 
 
Medication Adherence of Patient Assistance Program Recipients: A Pilot Study 
Christian S. Conley, PharmD
1 and Peter J. Hughes, PharmD, BCPS
2 
1Health-System Pharmacy Administration Resident, University of North Carolina Hospitals and 
2McWhorter School of Pharmacy, 
Samford University 
 
Abbreviations: MMAS=Morisky Medication Adherence Scores, MPR=Mean Possession Ratio, PAP=Patient Assistance Program 
Acknowledgements: Anna Meador, PharmD, Assistant Professor, McWhorter School of Pharmacy 
Conflict of interest: The authors declare no conflict of interest 
Funding: Self-funded 
Keywords: Medication, Adherence, Patient-Assistance 
 
Abstract 
Purpose: Evaluate medication adherence of prescription assistance program recipients at an inner-city clinic.  
Methods:  Surveys were administered at enrollment and 6 months following enrollment to patients who were either recipients of at 
least one patient assistance program (PAP) or had prescription benefits through Alabama Medicaid.  Data on patient demographics, 
Morisky Medication Adherence Survey (MMAS) scores, mean possession ratio (MPR), and drug classes were collected for 6 months.  
Results: The baseline MMAS score concluded that both the PAP group and Alabama Medicaid group were highly motivated and 
highly knowledgeable regarding adherence to prescribed medications.  After 6 months, administration of the same MMAS instrument 
resulted in a category change in the PAP group from highly motivated and knowledgeable to low motivation and high knowledge.  
The Medicaid MMAS adherence category did not change from baseline after 6 months.  The 6-month mean MPR for the PAP and 
Medicaid groups were 0.542 and 0.823, respectively.  
Conclusion: Providing free or low-cost medication plus customary counseling should not be the sole interventions for the uninsured 
patient.  In this study, PAP recipient MMAS score change and low mean MPR suggest that additional interventions are needed to 
ensure that PAP recipients adhere to prescribed therapies.  
__________________________________________________________________________________________ 
 
Introduction 
The United States Department of Commerce reported that 
the number of Americans without health insurance rose 2% 
to 49.9 million in 2010.
1 In addition, from 2009 to 2010 the 
number of Americans in poverty rose 6% from 43.6 million to 
an 46.2 million; the fourth consecutive year of increased 
poverty statistics, and the largest number documented in the 
52 years of evaluation.
1  Having health insurance allows the 
insured member more affordable care, and increased access 
of services through networks between the health insurance 
company and health care providers.  Access to health care 
impacts: overall physical, social, and mental health status, 
prevention of disease and disability, detection and treatment 
of health conditions, quality of life, preventable death, and 
life expectancy.
2  However, the uninsured lacks the 
affordability and access to medical services, and is less likely 
to receive medical care, more likely to die early, and have 
worsened health status.
3  
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While the percentage varies between states, 14% of Alabama 
residents are uninsured.
4  Alabama is recognized as one of 
several states that make up not only the “Stroke Belt” of the 
United States, but also the “Diabetes Belt.” 
5  Compared to 
other states, Alabama has one of the highest rates of death 
from cardiovascular disease, stroke, incidence of diabetes, 
hypertension and obesity.
6 The combination of the overall 
poor health of Alabama residents coupled with the 
exceptionally high rates of uninsured residents is particularly 
troubling.  
 
Preventative care for uninsured Alabama residents should be 
a top priority in order to prevent health-related 
complications, hospitalization, and death.  One primary and 
secondary preventative intervention is the use of prescription 
medications.  Many chronic disease states and their 
complications can be prevented or delayed with the use of 
prescription medications in concert with lifestyle 
modifications.  Stroke, hypertension, diabetes and 
cardiovascular disease can all be treated with medications 
that can decrease the progression to end organ damage or 
acute events.   
 
For the uninsured, drug cost can account for a substantial 
percentage of monthly income.
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often faced with the choice of paying for basic needs like food 
or rent in lieu of paying for their drugs, often resulting in non-
adherence with drug regimens.   By complying with proper 
treatment regimens, patients are less likely to develop 
secondary disease associated with improper pharmaceutical 
compliance.
8 
 
Pharmaceutical manufacturer prescription assistance 
programs (PAPs) offered by pharmaceutical manufacturers 
assist the uninsured by providing free or partially subsidized 
medication.  Pharmaceutical manufacturers offer these 
programs not only to aid indigent patients, but also reduce 
bad debt resulting from uncompensated medication 
assistance at institutions serving large indigent populations.
9 
While these programs do have some negative attributes, 
study results demonstrate positive outcomes to both patients 
and the healthcare system.
7,10,11   
 
The purpose of this study was to evaluate medication 
adherence of PAP recipients at an inner-city clinic.  The 
primary endpoint was to compare if a difference was present 
in medication adherence between PAP recipients and 
Alabama Medicaid recipients using a modified, 6-item 
Morisky Medication Adherence Scale (MMAS).  The 
secondary endpoint was to determine if a difference was 
present in the medication possession ratio MPR between the 
two groups.   
 
Methods 
This 6-month survey-based study aimed to evaluate 
medication adherence of PAP medication recipients within an 
inner-city clinic.   The modified MMAS was utilized to 
evaluate whether there is a difference in medication 
adherence among PAP recipients and Alabama Medicaid 
beneficiaries.  All new and existing PAP recipients and 
Alabama Medicaid pharmacy patrons of Christ Health Center 
(Birmingham, AL) who consented to participate completed a 
MMAS at baseline and 6 months from the initial study 
interview. Differences in MPR scores were also calculated. 
 
The MMAS is a validated, self-reported questionnaire that is a 
commonly used tool to assess a person’s medication 
adherence behavior. The MMAS is a 4-8 question survey that 
is designed to measure a specific medication-taking 
behavior.
12 Use of the modified MMAS is common in 
biomedical and professional literature and is customized to 
address circumstances surrounding adherence behavior 
related to a particular disease state.
 12-14  Scoring is based on 
yes/no answers that are then scored by an administrator.
12 
Score and intent to adhere to a prescribed medication 
regimen share a direct relationship (See Table 1).   
The MPR is calculated by dividing the total days’ supply of the 
medication by the total number of days within the period of 
analysis.
15 This calculation is used to evaluate how much 
medication a patient received over a period of observation, 
compared to the amount the patient should have ideally 
obtained.
15   A MPR equal to one represents absolute 
adherence and serves as a benchmark.  
 
The intervention group in this research consisted of existing 
Christ Health Center PAP recipients and newly enrolled PAP-
eligible patients.  All participants of the intervention group 
received an initial baseline interview by the staff pharmacist 
where they were provided with an informed consent form 
and a verbal explanation of the aims of the study.  The 
interview assessed patient demographics and baseline 
medication adherence intent.  Approximately 6 months 
following the initial interview, participants completed an 
additional MMAS form. 
 
The control group consisted of existing and new clinic 
patients or pharmacy patrons who were Alabama Medicaid 
beneficiaries.  As a health and pharmacy benefit program for 
uninsured children and the poor, Medicaid beneficiaries 
represent the most reliable option for a control comparison 
that share the most similar socioeconomic demographics to 
patient-assistance beneficiaries.  Identical to the intervention 
group, all participants in the control group were provided 
with an informed consent form with verbal explanation of the 
study and completed a baseline MMAS form at the initial 
visit, and 6 months after the initial interview.   
After the initial interview all participants in both the 
intervention and control groups received the pharmacist’s 
usual and customary counseling as required by law.  Exclusion 
criteria for the study were all patients who were less than 19 
years of age, patients who were not able to read or interpret 
the survey independently, and patients who did not complete 
the baseline MMAS questionnaire.  Once the 6-month study 
term was completed, an evaluation was conducted to 
determine if a difference in medication adherence and 
behaviors leading to adherence among and between the two 
study groups was present from baseline to study endpoint.   
Results 
Demographics 
Of the twenty patients who enrolled in the study, twelve 
received medication through PAPs and eight through 
Alabama Medicaid.  Baseline demographics are presented in 
Table 2.  The mean age and gender distribution of the two 
study groups were relatively similar.  The Medicaid group had 
significantly higher proportion of African Americans (75%) 
compared to the PAP group (41.6%).  Caucasians were the 
most common racial group in the PAP group (50%), but Original Research  PHARMACY PRACTICE 
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represented only 12.5% of the Medicaid group. The Medicaid 
group consisted mostly of high school graduates (50%), 
whereas 75% of the PAP group documented having some 
college.   
 
Morisky Medication Adherence Scale 
The baseline MMAS results for both groups are presented in 
Table 3.  Both groups had a higher percentage of “No” 
answers for questions 2, 3, and 4, and a higher percentage of 
“Yes” answers to question 5.  After scoring the MMAS 
questions, a majority of patients in both groups were 
categorized as highly motivated and highly knowledgeable in 
regards to adhering to their medication regimen.   
 
As shown in Figure 1, the Medicaid group represented 
individuals (75.5%) with high motivation and high knowledge 
compared to 41.5% for the PAP group.  There were no 
patients in the Medicaid group categorized with high 
motivation and low knowledge compared to 8.3% in the PAP 
group.  The Medicaid group did have 12.5% of patients with 
low motivation and high knowledge versus 33.3% in the PAP 
group.  The proportion of results corresponding with low 
motivation and low knowledge were similar in both Medicaid 
and PAP patients, 12.5% and 16.6%, respectively.  
 
The second MMAS results at 6 months are shown in Figure 2.  
In the Medicaid group, 100% of the patients who completed 
the survey were categorized as patients with high motivation 
and high knowledge.  For those who completed the second 
MMAS in the PAP group, 100% were categorized with low 
motivation and high knowledge.   
 
Medication Possession Ratio 
Of the eight Medicaid patients completing the study, the 
mean MPR was 82.3% ± 19.6%.  For the twelve PAP patients, 
the mean MPR was 54.2% ±34%.  Medications used within 
each group are shown in Table 4.  
 
Discussion 
One advantage of PAPs is the potential for increased 
medication adherence secondary to provision of free or low-
cost medication.  A prospective cohort study conducted by 
Schoen et al, investigated whether cardiovascular outcome 
measures (INR ratio, blood pressure, LDL cholesterol, 
hospitalizations) and drug adherence had an effect in indigent 
patients who received PAP medications.  After the 6-month 
long study, the mean LDL levels for patients on lipid lowering 
drugs significantly decreased from 126 +-39mg/dl to 108 +- 
38mg/dl (p< 0.001).
7 Hospitalization events for the entire 
cohort decreased from 85 at baseline to 49 at 6 months.  
Medication adherence improved from 48.5% to 72.7% at 6 
months (p<0.001).
7 
Marrs et al conducted a retrospective medical record review 
that evaluated dyslipidemia control in indigent patients 
receiving medication assistance versus insured patients.
10  
The primary objective of the study was LDL goal attainment 
rates and use of a lipid lowering regimen that provides at 
least a 30% reduction in LDL.  A secondary objective was the 
percent of patients with MPR values of at least 75% during 
the study period compared between the two study groups.
  
The intervention resulted in a 68.9% LDL goal achievement 
for indigent patients enrolled in the PAP versus 78.4% of 
insured patients (p=0.34).
 12 Even though the study resulted in 
non-significant values for LDL control, the MPR >75% was 
statistically significant for PAP patients.  The PAP group had 
more patients reaching an MPR threshold of >75% versus the 
insured group, 48.5% vs. 15%, respectively (p=<0.001).
 10 
 
Similarly, Strum et al conducted a retrospective analysis of 
type 2 diabetes patients receiving mediation through a 
medication assistance program.
11 Medications included in the 
evaluation were diabetic, antihypertensive and lipid-lowering 
medications.  Pre- and post-enrollment disease indicators 
were evaluated.  Hemoglobin A1C (%) pre- and post-
enrollment were 9.3±2.4 and 8.5 ±1.5, respectively (p=0.018), 
total cholesterol was 196 +-40 mg/dL and 183 ±38 mg/dL, 
respectively (p=0.017) and LDL levels were 118±36 mg/dL and 
102 ±31 mg/dL, respectively (p=<0.001).
11  
 
These findings suggest that clinic-based PAPs can improve 
patient outcomes. In theory, medication assistance programs 
seem beneficial.  The uninsured are able to obtain medication 
they would otherwise not be able to afford.  PAPs  have the 
potential to improve prescription drug accessibility for 
eligible patients, but currently there is limited information 
regarding their effectiveness.
14  No formal entity is 
responsible for tracking utilization of PAPs or evaluating their 
effectiveness, nor are there readily available public data on 
the use of PAPs.
16  Furthermore, even when prescription 
drugs are made available to patients free of charge through 
PAPs, patients may face other costs (e.g., transportation) that 
can restrict their access.
16  There are several dimensions of 
adherence that include health system factors, 
social/economic factors, condition-related factors, therapy-
related factors, and patient-related factors.
17   All of these 
factors contribute to a patient’s intent and motivation to 
adhere to a prescribed drug regimen.  
 
In this study, we used both the MMAS and MPR to evaluate 
medication adherence in PAP recipients versus patients with 
Alabama Medicaid prescription coverage.  From the MMAS 
scoring at baseline, both groups had the highest percentage 
of patients categorized with high motivation and high 
knowledge to medication adherence (Medicaid, 75.5%; PAP, Original Research  PHARMACY PRACTICE 
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41.5%).  In addition, 12.5% of the Medicaid patients and 
16.6% of PAP recipients were categorized with low 
motivation and low knowledge.  Based solely from the 
baseline MMAS scores, one can infer that throughout the 6-
month evaluation, the majority of patients in both groups 
would have high adherence rates.  However, results from the 
MPR showed inconsistencies in the PAP group.   Even though 
majority of participants in the PAP group were categorized 
with high motivation and high knowledge, the mean MPR was 
only 52.2%, whereas the Medicaid group had a mean MPR of 
82.3%.  
 
Even though the number of participants who completed the 
second MMAS survey was extremely low, the results appear 
more consistent with the MPR results.  Interpretation of the 
results suggests that the PAP recipients at baseline were 
highly motivated and knowledgeable about taking their 
medication.  However, over time the PAP recipients lost 
motivation to take their medication as prescribed by the 
physician.   
 
Due to the low enrollment of participants into the study 
inferential statistics were not conducted.  However, results 
from the study provide insight into the need for additional 
interventions addressing medication adherence among PAP 
recipients.  These data suggest that for PAP recipients, 
behavior-based interventions and counseling focusing on 
increasing adherence motivation could be potentially 
beneficial.   
 
Limitations  
This study had several limitations that must be considered 
when interpreting the results.  First, the sample size was 
extremely low.  The low sample size was likely the result of 
two factors: the willingness of Christ Health Center patients 
to participate in the study and the difficulty of incorporating 
and managing the study on top of the staff’s normal daily 
activities.  At the end of 6 months we attempted to contact 
the study participants to return to Christ Health Center to 
complete the second MMAS survey.  Of the 20 participants 
enrolled, only four completed the post-enrollment survey, 
two from each study group.  This posed a tremendous barrier 
in comparing MMAS results from baseline to 6 months.  Of 
the two PAP recipients who completed the second MMAS 
survey, both scores resulted in a category change from high 
motivation and knowledge to low motivation and high 
knowledge.  The two Medicaid participant scores did not 
change from baseline.   
 
The MMAS questionnaire is a cost effective method of 
evaluating medication adherence, but this method does pose 
limitations.  Since the MMAS is a self-reported method of 
evaluation, one must take into consideration personal bias, 
misinterpretation of survey questions, and reliance of the 
participant’s recall.  In addition, surveys conducted while 
treatment is ongoing can also create a “Hawthorne Effect” 
(the tendency of patients to increase compliance because 
they know they are being observed).
15 Even though using 
pharmacy claims to calculate the MPR is a good method of 
avoiding the Hawthorne Effect, the MPR provides no 
information on why a patient might have stopped taking his 
or her medication.  This method also does not have the ability 
to determine how long the physician decides to treat the 
patient with a specific medication.  
 
Conclusion 
PAPs are a resource that health care professionals can use to 
help the uninsured obtain medications. However, access to 
free or low-cost medication and usual counseling should not 
be the only interventions.  Health care professionals should 
augment the provision of subsidized medication with 
behavioral interventions that focus on the patient’s 
motivation to adhere to a specific medication regimen.  
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Table 1. MMAS Scoring 
 
Morisky Questions  Motivation  Knowledge 
1. Do you sometimes forget to take your medication?  Yes (0) No (1)   
2. Are you careless at times about taking your medicine?  Yes (0) No (1)   
3. When you feel better, do you sometimes stop taking your 
medicine? 
  Yes (0) No (1) 
4. Do you ever stop taking this medication if it makes you feel 
worse? 
  Yes (0) No (1) 
5. Do you know the long-term benefits of taking this medicine as 
told to you by your doctor or pharmacist?  
  Yes (1) No (0) 
6. Sometimes do you forget to refill your prescription medicine 
on time?  
Yes (0) No (1)   
Total Score   0-1= Low Motivation  
2-3= High Motivation 
0-1=Low Knowledge  
2-3=High Knowledge  
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Table 2. Demographics 
 
Variables  Medicaid Group  (n)  Prescription Assistance Group (n) 
Mean age (years)  43  42 
 
Gender, %  Female: 75  (6)  Female: 66 (8) 
 
Race, %  African American: 75 (6) 
Caucasian: 12.5 (1) 
Other: 12.5 (1) 
African American: 41.6 (5) 
Caucasian: 50 (6) 
Hispanic: 8.3 (1) 
 
Education, %  High School Grad: 50 (4) 
Some High School: 37.5 (3) 
Some College: 12.5 (1) 
High School Grad: 16.6 (2) 
Some College: 75 (9) 
College Grad: 8.3 (1) 
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Table 3.  Baseline MMAS Results 
 
Morisky Questions  Patient Assistance  Medicaid 
  Yes 
[X] 
No 
[X] 
Yes 
[X] 
No 
[X] 
1. Do you sometimes forget to take your medication?  58.3% 
(7) 
41.6% 
(5) 
37.5% 
(3) 
62.5% 
(5) 
2. Are you careless at times about taking your medicine? 
 
16.6% 
(2) 
83.3% 
(10) 
25% 
(2) 
75% 
(6) 
3. When you feel better, do you sometimes stop taking your medicine? 
 
25% 
(3) 
75% 
(9) 
12.5% 
(1) 
87.5% 
(7) 
4. Do you ever stop taking this medication if it makes you feel 
worse? 
33.3%  
(4) 
66.6%  
(8) 
(0)  100% 
(8) 
5. Do you know the long-term benefits of taking this medicine as 
told to you by your doctor or pharmacist?  
75% 
(9) 
25% 
(3) 
62.5% 
(5) 
37.5% 
(3) 
6. Sometimes do you forget to refill your prescription medicine on 
time?  
58.3% 
(7) 
41.6% 
(5) 
25% 
(2) 
75% 
(6) 
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Table 4. Medications per study group 
 
Patient Assistance Group  Medicaid Group 
Apidra*  aspirin 
Benicar*  atenolol 
Crestor*      Coreg* 
Cymbalta*  Lexapro* 
Flovent*  lisinopril 
Lantus Solostar*  metformin 
Nexium*  pravastatin 
Seroquel*  Spiriva* 
Spiriva*   
Tricor*   
Tribenzor*   
Uroxatral*   
   
* Brand name drug dispensed  
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